Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Swisher

Showing results (81-90 of 194) with videos related to

Pageof 20
Sort By:
Gynecologic Oncology|June 11, 2021
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trialCarol Aghajanian, Michael A Bookman, Gini F Fleming, et al.
Gynecologic Oncology|September 19, 2012
Loss of function germline mutations in RAD51D in women with ovarian carcinomaAnneka Wickramanayake, Anneka Wickramanyake, Greta Bernier, et al.
Gynecologic Oncology|February 27, 2019
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinomaChristopher B Morse, Mirna N Toukatly, Mark R Kilgore, et al.
American Journal of Obstetrics and Gynecology|November 3, 2025
Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precautionRoni Nitecki Wilke, Kathryn P Pennington, Tamar A Gootzen, et al.
JCO Precision Oncology|October 5, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian CancerLinda R Duska, Dmitriy Zamarin, Erica Hamilton, et al.
Gynecologic Oncology|December 25, 2012
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testingBarbara M Norquist, Kathryn P Pennington, Kathy J Agnew, et al.
Molecular Cancer Therapeutics|January 29, 2021
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell CarcinomaShogo Shigeta, Goldie Y L Lui, Reid Shaw, et al.
Gynecologic Oncology|March 31, 2015
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group studyRobert L Coleman, Michael W Sill, Katherine Bell-McGuinn, et al.
Gynecologic Oncology|April 18, 2025
TP53 somatic evolution in the normal endometrium of Black and White individualsEric Rios-Doria, Elizabeth U Parker, Brendan F Kohrn, et al.
Gynecologic Oncology|June 10, 2017
Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White PaperLeslie M Randall, Bhavana Pothuri, Elizabeth M Swisher, et al.
Pageof 20

Showing results (81-90 of 194) with videos related to

Sort By:
Pageof 20
Gynecologic Oncology|June 11, 2021
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trialCarol Aghajanian, Michael A Bookman, Gini F Fleming, et al.
Gynecologic Oncology|September 19, 2012
Loss of function germline mutations in RAD51D in women with ovarian carcinomaAnneka Wickramanayake, Anneka Wickramanyake, Greta Bernier, et al.
Gynecologic Oncology|February 27, 2019
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinomaChristopher B Morse, Mirna N Toukatly, Mark R Kilgore, et al.
American Journal of Obstetrics and Gynecology|November 3, 2025
Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precautionRoni Nitecki Wilke, Kathryn P Pennington, Tamar A Gootzen, et al.
JCO Precision Oncology|October 5, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian CancerLinda R Duska, Dmitriy Zamarin, Erica Hamilton, et al.
Gynecologic Oncology|December 25, 2012
Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testingBarbara M Norquist, Kathryn P Pennington, Kathy J Agnew, et al.
Molecular Cancer Therapeutics|January 29, 2021
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell CarcinomaShogo Shigeta, Goldie Y L Lui, Reid Shaw, et al.
Gynecologic Oncology|March 31, 2015
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group studyRobert L Coleman, Michael W Sill, Katherine Bell-McGuinn, et al.
Gynecologic Oncology|April 18, 2025
TP53 somatic evolution in the normal endometrium of Black and White individualsEric Rios-Doria, Elizabeth U Parker, Brendan F Kohrn, et al.
Gynecologic Oncology|June 10, 2017
Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White PaperLeslie M Randall, Bhavana Pothuri, Elizabeth M Swisher, et al.
Pageof 20